The Pentagon is testing a big idea: can orbit take over part of the airborne-tracking mission long handled by AWACS-type aircraft?

Our latest on space-based AMTI, the U.S. Space Force, and what this could mean for future air combat:

#SpaceTech #DefenseTech #SpaceForce #Pentagon #AMTI #AWACS

Why UCB Is Betting $1.15 Billion That Cell Therapy Can Change Epilepsy - Biotech Industry Examiner The April 17, 2026 deal is a wager that a one-time neural cell therapy can push epilepsy treatment beyond symptom management — and make regenerative medicine

UCB’s $1.15B Neurona Therapeutics acquisition is a high-stakes bet on cell therapy in epilepsy. The bigger question: can biotech move from suppressing seizures to repairing brain circuits?

#Biotech #UCB #NeuronaTherapeutics #Epilepsy #CellTherapy #TechNews

Amazon’s Globalstar move strengthens its D2D push and Apple link. It still doesn’t solve the launch bottleneck — and that’s why Starlink remains ahead.

spacetech.industryexaminer.com/amazon-globa...
#SpaceTech #SatelliteInternet #Amazon #Globalstar #AmazonLeo #Starlink #SpaceX #Apple #TechNews

Britain’s £50 Million AgTech Push Is Really a Commercialization Story - Agtech Industry Examiner The UK’s latest farm-tech package matters not simply because it backs a dozen near-market tools, but because it reveals where […]

Britain’s £50M agtech push is really about commercialization, not just invention. The real challenge is getting farm tech from prototype to adoption. Read: agtech.industryexaminer.com/britains-50-... #AgTech #Agriculture #TechNews

Wise's planned Nasdaq debut is a test of what public markets want from fintech now: hype, or infrastructure. Our latest argues that profitable cross-border payments may be one of the few models investors can still price with conviction. fintech.industryexaminer.com/wise-nasdaq-... #Fintech #IPO

The solar trade war may be moving upstream. Not panels, but the tools to make them. Our latest on why China’s equipment edge could shape America’s solar factory ambitions: climatetech.industryexaminer.com/china-solar-... #ClimateTech #Solar
#TechNews

Biotech IPOs are reopening—but selectively.

Kailera Therapeutics and Alamar Biosciences show what the market wants now: late-stage, legible stories investors can actually underwrite.

Our latest:
biotech.industryexaminer.com/biotech-ipo-...

#Biotech #IPO #CapitalMarkets #LifeSciences #TechNews

Planet Labs’ Iran freeze raises a bigger question: who controls the view from orbit when commercial imagery is restricted in a crisis? spacetech.industryexaminer.com/planet-iran-... #SpaceTech #SpacePolicy #RemoteSensing #TechNews

Swiss banks aren’t just testing a franc stablecoin. They’re testing whether domestic banks can shape the next layer of digital money before dollar tokens become the default rail.
#Fintech #Stablecoins #Payments #Banking #Switzerland #DigitalMoney #TechNews #IndustryExaminer \

China’s “new energy system” looks less like climate branding and more like strategic insulation

Our new analysis on how Beijing is turning solar, storage, grids, nuclear, hydropower and EVs into an energy-security doctrine
#ClimateTech #China #EnergySecurity #Renewable #EnergyTransition #PowerGrid

The headline says Biogen bought Apellis Pharmaceuticals for $5.6 billion.

The deeper story is that biotech may be starting to see kidney disease not as a difficult niche, but as a strategic market worth building around.

#Biotech #KidneyDisease #Nephrology #Biogen #TechNews

Crop protection’s next race is not biology vs chemistry. It’s a search for a broader toolbox. BASF’s AgBiTech deal, Bayer’s new herbicide push, and Bindbridge’s protein-degradation bet all point to the same shift. agtech.industryexaminer.com/crop-protect... #AgTech #CropProtection #TechNews

NASA’s Moon Base Plan Is Really a Bet on Lunar Logistics - Spacetech Industry Examiner By pausing Gateway in its current form and redirecting Artemis toward the lunar south pole, NASA is not just changing mission architecture. It is betting that

NASA’s moon base plan is really a bet on lunar logistics.

Not just landings — but cargo, power, cadence, mobility, and the supply chain needed to sustain operations at the lunar south pole.

That may be the real moonshot.

#SpaceTech #NASA #Artemis #MoonBase #LunarEconomy #TechNews

Money is becoming software — but the real question is whose money, on what rails, and under what rules.

Our latest feature explores why #BMO, CME Group, and #Google Cloud may be pointing toward one of fintech’s biggest next shifts: tokenized bank money built for a 24/7 financial system.

#Fintech

AI’s Next Bottleneck Is Electricity — and Climate Tech May Be the Real Winner - ClimateTech Industry Examiner Crusoe’s latest battery deals are not really about batteries. They are about what happens when AI collides with the grid — and why the next winners in climate

AI’s next bottleneck may not be chips.

It may be electricity.

Our latest feature argues the AI race is becoming an infrastructure race — and that batteries, grid flexibility, substations, and power delivery could matter more than many expected.

#ClimateTech #AI #DataCenters #Grid #TechNews

Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.

When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.

#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechNews

The old ranch was built with wire. The next one may be drawn on a smartphone.

Halter’s $220M raise is a fascinating test of whether virtual fencing is becoming real infrastructure, not just an agtech demo.

#AgTech #VirtualFencing #LivestockTech #Ranching #TechNews #IndustryExaminer

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure. - Biotech Industry Examiner Roche’s latest Nvidia build is not just another AI headline. It is a sign that in biotech, the next real advantage may come from owning the compute, data and

Biotech AI is becoming an infrastructure race.

Roche’s latest Nvidia build points to a bigger shift: the next pharma moat may come from compute, data and workflows at scale.

biotech.industryexaminer.com/biotech-ai-i...

#Biotech #AI #Pharma #Roche #NVIDIA #TechNews #IndustryExaminer

Anduril’s ExoAnalytic deal is about more than telescopes. It’s a bet that the next edge in missile defense will come from owning the orbital picture: tracking, data, software, and command.

#SpaceTech #DefenseTech #GoldenDome #MissileDefense #TechNews #DeepSpace

London’s fintech rise is not just a ranking story. It reflects a deeper shift in what the market rewards: regulation, infrastructure, institutional depth, and resilience over hype.

Our latest feature:

#Fintech #London #UKFintech #VC #Payments #DigitalBanking #FintechNews #TechNews

The Next Solar Race Is Not About Cost. It’s About Reliability. - ClimateTech Industry Examiner Masdar’s giant Abu Dhabi project is designed to do something solar has rarely been asked to do at utility scale: deliver a steady block of electricity around

Solar won the cost argument years ago. The harder test is reliability.
Masdar’s Abu Dhabi project pairs 5.2 GW of solar with 19 GWh of storage to target 1 GW of round-the-clock power. That could reshape how clean power is sold.

#ClimateTech #Solar #EnergyStorage #TechNews #SolarNews #Masdar

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation - Biotech Industry Examiner The rovadicitinib deal is about more than one blood-cancer and transplant asset. It is another sign that global pharma is no longer treating China mainly as a

China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.

Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.

#Biotech #Pharma #ChinaBiotech #BiotechNews #TechNews

Biologicals want to go mainstream.
They may first have to earn it on the seed.
Our latest #AgTech feature looks at why seed treatment could become the real proving ground for crop biologicals — with Ascribe Bio, Corteva, and the wider competitive context around Syngenta and BASF.
#Biologicals

Sierra Space’s $550M raise at an $8B valuation is more than a funding headline. It shows what private space is being rewarded for now: defense relevance, factory capacity, and execution.
spacetech.industryexaminer.com/sierra-space...

#SpaceTech #DefenseTech #Aerospace #TechNews #SpaceNews

Revolut’s U.S. bank-charter bid isn’t just an expansion play—it’s a bet on governance.

A charter means deposits + lending control, but also bank-grade scrutiny: BSA/AML, resilience, consumer compliance, board oversight.
#FinTech #DigitalBanking #Regulation #TechNews #BankingNews #RegTech

Europe’s Industrial Accelerator Act: “Buy EU,” but Make It Low-Carbon - ClimateTech Industry Examiner On March 4, the European Commission unveiled the Industrial Accelerator Act (IAA)—a legislative proposal that reads like a memo from an anxious boardroom:

Europe is turning climate targets into procurement rules. The proposed Industrial Accelerator Act aims to lift manufacturing from 14.3% of EU GDP (2024) to 20% by 2035 — with “lead markets” for low-carbon steel/cement/aluminium + local-content EV rules.
#ClimateTech #EU #IndustrialPolicy #TechNews

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing - Biotech Industry Examiner On March 2, 2026, the U.S. Food and Drug Administration removed the clinical hold on Intellia Therapeutics’ MAGNITUDE Phase 3 trial—restarting a program that

FDA lifted the clinical hold on Intellia’s MAGNITUDE Phase 3 (ATTR-CM). The headline says “resume.”

The real story: a safety reset—tighter selection + heavier liver monitoring + explicit mitigation steps.

biotech.industryexaminer.com/crispr-safet...

#CRISPR #Biotech #ClinicalTrials #TechNews

Waste to Yield: The Vietnam Rice Trial Claiming a 43% Jump—and the Questions That Matter - Agtech Industry Examiner A 43% yield increase is the kind of number that makes agronomists squint. That’s exactly what a recent field demonstration […]

Vietnam rice trial: waste-derived biostimulant, +43% yield (688.7 vs 482.8 kg/0.1 ha). Big upside—but ask: replications? fertilizer rates? multi-season proof? Read: agtech.industryexaminer.com/waste-to-yie...
#AgTech #Biostimulants #Rice #Vietnam #SustainableAgriculture #TechNews

Space Force gave Mission Delta 9 a live satellite (launched on USSF-87, Feb 12) to practice “precise, advanced” GEO maneuvers. In space, movement = fuel + lifespan + signaling (and escalation risk). spacetech.industryexaminer.com/space-force-...
#SpaceForce #SpaceTech #GEO

Stripe: $1.9T. PayPal: $1.79T + 439M accounts. If Stripe buys PayPal (or parts), the prize isn’t volume—it’s checkout identity: who gets to say “yes.” Read: fintech.industryexaminer.com/stripe-paypa...
#Fintech #Payments #PayTech #MergersAndAcquisitions #Stripe #PayPal #TechNews